Abstract: The incidence of osteoporosis is increasing year by year, causing economic burden to the society. Peri-menopausal women are more susceptible to osteoporosis due to serum hormone level and aging. Until recently, the underlying mechanisms have been primarily attributed to estrogen deficiency, but bone loss in women commences is prior to the onset of menopause and estrogen deficiency. The level of serum FSH increases as early as 6 years before the final menstrual period. Several studies have found that FSH is correlated with bone turnover markers and bone mineral density, which may be one of the causes of peri-menopausal bone loss. FSH not only acts on gonads through FSH receptors (FSHR), but also acts on osteoclasts and bone metabolism. FSH promotes osteoclasts formation, maturation and differentiation through signaling pathways, cytokines and immune factors.This article mainly reviews the relationship, the mechanism, the clinical application between FSH and peri-menopausal osteoporosis, which aims to provide new ideas for the prevention and treatment of perimenopausal osteoporosis.

Key words: Perimenopause, Osteoporosis, Follicle stimulating hormone;, Bone mineral density, Osteoclasts